Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration

HIV-2 and SIVMAC are AIDS-causing, zoonotic lentiviruses that jumped to humans and rhesus macaques, respectively, from SIVSM-bearing sooty mangabey monkeys. Cross-species transmission events such as these sometimes necessitate virus adaptation to species-specific, host restriction factors such as TRIM5. Here, a new human restriction activity is described that blocks viruses of the SIVSM/SIVMAC/HIV-2 lineage. Human T, B, and myeloid cell lines, peripheral blood mononuclear cells and dendritic cells were 4 to >100-fold less transducible by VSV G-pseudotyped SIVMAC, HIV-2, or SIVSM than by HIV-1. In contrast, transduction of six epithelial cell lines was equivalent to that by HIV-1. Substitution of HIV-1 CA with the SIVMAC or HIV-2 CA was sufficient to reduce HIV-1 transduction to the level of the respective vectors. Among such CA chimeras there was a general trend such that CAs from epidemic HIV-2 Group A and B isolates were the most infectious on human T cells, CA from a 1° sooty mangabey isolate was the least infectious, and non-epidemic HIV-2 Group D, E, F, and G CAs were in the middle. The CA-specific decrease in infectivity was observed with either HIV-1, HIV-2, ecotropic MLV, or ALV Env pseudotypes, indicating that it was independent of the virus entry pathway. As2O3, a drug that suppresses TRIM5-mediated restriction, increased human blood cell transduction by SIVMAC but not by HIV-1. Nonetheless, elimination of TRIM5 restriction activity did not rescue SIVMAC transduction. Also, in contrast to TRIM5-mediated restriction, the SIVMAC CA-specific block occurred after completion of reverse transcription and the formation of 2-LTR circles, but before establishment of the provirus. Transduction efficiency in heterokaryons generated by fusing epithelial cells with T cells resembled that in the T cells, indicative of a dominant-acting SIVMAC restriction activity in the latter. These results suggest that the nucleus of human blood cells possesses a restriction factor specific for the CA of HIV-2/SIVMAC/SIVSM and that cross-species transmission of SIVSM to human T cells necessitated adaptation of HIV-2 to this putative restriction factor.

[1]  Charles M. Rice,et al.  Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response , 2015, Nature.

[2]  J. Luban,et al.  Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration , 2014, Retrovirology.

[3]  J. Luban,et al.  Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA , 2014, Retrovirology.

[4]  Ryan C. Burdick,et al.  Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes , 2013, Proceedings of the National Academy of Sciences.

[5]  Shilei Ding,et al.  The interferon-inducible MxB protein inhibits HIV-1 infection. , 2013, Cell host & microbe.

[6]  Charles M. Rice,et al.  MX2 is an interferon-induced inhibitor of HIV-1 infection , 2013, Nature.

[7]  B. Hahn,et al.  Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d’Ivoire , 2013, AIDS.

[8]  M. Malim,et al.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection , 2013, Nature.

[9]  S. Antonarakis,et al.  TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm , 2013, Retrovirology.

[10]  B. Verhasselt,et al.  Quantification of Reverse Transcriptase Activity by Real-Time PCR as a Fast and Accurate Method for Titration of HIV, Lenti- and Retroviral Vectors , 2012, PloS one.

[11]  J. Luban,et al.  The Carboxyl-Terminus of Human Immunodeficiency Virus Type 2 Circulating Recombinant form 01_AB Capsid Protein Affects Sensitivity to Human TRIM5α , 2012, PloS one.

[12]  J. Luban,et al.  TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. , 2012, Current opinion in virology.

[13]  J. Luban,et al.  Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus , 2011, Retrovirology.

[14]  R. J. Lai,et al.  Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41 , 2011, PLoS pathogens.

[15]  N. Landau,et al.  The Cargo-Binding Domain of Transportin 3 Is Required for Lentivirus Nuclear Import , 2011, Journal of Virology.

[16]  J. Luban,et al.  Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon , 2011, Retrovirology.

[17]  Á. McKnight,et al.  Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2. , 2011, Virology.

[18]  Jeremy Luban,et al.  TRIM5 is an innate immune sensor for the retrovirus capsid lattice , 2011, Nature.

[19]  M. Lederman,et al.  Origins of HIV and the AIDS Pandemic , 2011 .

[20]  D. Levy,et al.  A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells , 2010, Nature.

[21]  P. Sharp,et al.  The evolution of HIV-1 and the origin of AIDS , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.

[22]  Ruchi M. Newman,et al.  TRIM5 Suppresses Cross-Species Transmission of a Primate Immunodeficiency Virus and Selects for Emergence of Resistant Variants in the New Species , 2010, PLoS biology.

[23]  Joerg Bewersdorf,et al.  Far-red fluorescent protein excitable with red lasers for flow cytometry and superresolution STED nanoscopy. , 2010, Biophysical journal.

[24]  A. Engelman,et al.  Flexible use of nuclear import pathways by HIV-1. , 2010, Cell host & microbe.

[25]  Jeremy Luban,et al.  Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. , 2009, The Journal of clinical investigation.

[26]  Jean-Yves Nau,et al.  [A new human immunodeficiency virus derived from gorillas]. , 2009, Revue medicale suisse.

[27]  R. Bartenschlager,et al.  Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics , 2009, PLoS pathogens.

[28]  J. Jones,et al.  Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz , 2009, Nature.

[29]  E. Eichler,et al.  Comparative analysis of Alu repeats in primate genomes. , 2009, Genome research.

[30]  M. Mcclure,et al.  A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. , 2009, Journal of virological methods.

[31]  Jeremy Luban,et al.  An Invariant Surface Patch on the TRIM5α PRYSPRY Domain Is Required for Retroviral Restriction but Dispensable for Capsid Binding , 2009, Journal of Virology.

[32]  Matthew Cotten,et al.  HIV-2: the forgotten AIDS virus. , 2008, Trends in microbiology.

[33]  C. Aiken,et al.  Proteasomal Degradation of TRIM5α during Retrovirus Restriction , 2008, PLoS pathogens.

[34]  D. Kohn,et al.  Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors , 2008, Gene Therapy.

[35]  T. Hope,et al.  Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5α , 2008, The Journal of cell biology.

[36]  P. Uchil,et al.  TRIM E3 Ligases Interfere with Early and Late Stages of the Retroviral Life Cycle , 2008, PLoS pathogens.

[37]  M. Emerman,et al.  Evidence for Direct Involvement of the Capsid Protein in HIV Infection of Nondividing Cells , 2007, PLoS pathogens.

[38]  T. Schaller,et al.  An Active TRIM5 Protein in Rabbits Indicates a Common Antiviral Ancestor for Mammalian TRIM5 Proteins , 2007, Journal of Virology.

[39]  J. Overbaugh,et al.  A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. , 2007, Virology.

[40]  P. Sharp,et al.  Human immunodeficiency viruses: SIV infection in wild gorillas , 2006, Nature.

[41]  A. Engelman,et al.  Proteasome Inhibition Reveals that a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 Proteins , 2006, Journal of Virology.

[42]  J. Luban.  Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection , 2006, Journal of Virology.

[43]  M. Yap,et al.  All Three Variable Regions of the TRIM5α B30.2 Domain Can Contribute to the Specificity of Retrovirus Restriction , 2006, Journal of Virology.

[44]  Timothy P. L. Smith,et al.  Isolation of an Active Lv1 Gene from Cattle Indicates that Tripartite Motif Protein-Mediated Innate Immunity to Retroviral Infection Is Widespread among Mammals , 2006, Journal of Virology.

[45]  L. Wain,et al.  Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 , 2006, Science.

[46]  J. Sodroski,et al.  Functional Replacement of the RING, B-Box 2, and Coiled-Coil Domains of Tripartite Motif 5α (TRIM5α) by Heterologous TRIM Domains , 2006, Journal of Virology.

[47]  T. Hope,et al.  Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Engelman,et al.  Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Joseph Sodroski,et al.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Luban,et al.  Cyclophilin A and TRIM5α Independently Regulate Human Immunodeficiency Virus Type 1 Infectivity in Human Cells , 2006, Journal of Virology.

[51]  J. Luban,et al.  Arsenic Counteracts Human Immunodeficiency Virus Type 1 Restriction by Various TRIM5 Orthologues in a Cell Type-Dependent Manner , 2006, Journal of Virology.

[52]  D. Robertson,et al.  Kuru experiments triggered the emergence of pathogenic SIVmac. , 2006, AIDS.

[53]  J. Sodroski,et al.  Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains. , 2006, Journal of virology.

[54]  J. Olsen,et al.  Restriction of Feline Immunodeficiency Virus by Ref1, Lv1, and Primate TRIM5α Proteins , 2005, Journal of Virology.

[55]  D. Pérez-Caballero,et al.  Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity , 2005, Journal of Virology.

[56]  J. Luban,et al.  Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells , 2005 .

[57]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[58]  G. Towers,et al.  Differential Restriction of Human Immunodeficiency Virus Type 2 and Simian Immunodeficiency Virus SIVmac by TRIM5α Alleles , 2005, Journal of Virology.

[59]  S. Elledge,et al.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Robertson,et al.  Molecular Epidemiology of Simian Immunodeficiency Virus SIVsm in U.S. Primate Centers Unravels the Origin of SIVmac and SIVstm , 2005, Journal of Virology.

[61]  J. Luban,et al.  TRIM5α selectively binds a restriction-sensitive retroviral capsid , 2005, Retrovirology.

[62]  J. Luban,et al.  Disruption of Human TRIM5α Antiviral Activity by Nonhuman Primate Orthologues , 2005, Journal of Virology.

[63]  J. Sodroski,et al.  Retrovirus Restriction by TRIM5α Variants from Old World and New World Primates , 2005, Journal of Virology.

[64]  J. Sodroski,et al.  Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5α Determines the Potency of Human Immunodeficiency Virus Restriction , 2005, Journal of Virology.

[65]  Jonathan P. Stoye,et al.  A Single Amino Acid Change in the SPRY Domain of Human Trim5α Leads to HIV-1 Restriction , 2005, Current Biology.

[66]  J. Luban,et al.  Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Sodroski,et al.  Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. , 2005, Journal of virology.

[68]  J. Luban,et al.  Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. , 2005, Journal of virology.

[69]  S. Goff.  Retrovirus restriction factors. , 2004, Molecular cell.

[70]  Jeremy Luban,et al.  Target Cell Cyclophilin A Modulates Human Immunodeficiency Virus Type 1 Infectivity , 2004, Journal of Virology.

[71]  J. Luban,et al.  Lv1 Inhibition of Human Immunodeficiency Virus Type 1 Is Counteracted by Factors That Stimulate Synthesis or Nuclear Translocation of Viral cDNA , 2004, Journal of Virology.

[72]  A. Lackner,et al.  Classic AIDS in a Sooty Mangabey after an 18-Year Natural Infection , 2004, Journal of Virology.

[73]  S. Nisole,et al.  Trim5α protein restricts both HIV-1 and murine leukemia virus , 2004 .

[74]  G. Towers,et al.  The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. Yang,et al.  Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Luban,et al.  Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1 , 2004, Nature.

[77]  F. Brun-Vézinet,et al.  Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. , 2004, AIDS research and human retroviruses.

[78]  W. Sundquist,et al.  Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid , 2004, Journal of Virology.

[79]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[80]  David J. Marchant,et al.  Lv2, a Novel Postentry Restriction, Is Mediated by both Capsid and Envelope , 2004, Journal of Virology.

[81]  S. Nisole,et al.  Trim5alpha protein restricts both HIV-1 and murine leukemia virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  P. Spearman,et al.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  P. Bieniasz,et al.  Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors , 2003, Nature Medicine.

[84]  Martine Peeters,et al.  Hybrid Origin of SIV in Chimpanzees , 2003, Science.

[85]  P. Pandolfi,et al.  As2O3 Enhances Retroviral Reverse Transcription and Counteracts Ref1 Antiviral Activity , 2003, Journal of Virology.

[86]  P. Bieniasz,et al.  Restriction of multiple divergent retroviruses by Lv1 and Ref1 , 2003, The EMBO journal.

[87]  G. Lucero,et al.  A dominant block to HIV-1 replication at reverse transcription in simian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[88]  P. Bieniasz,et al.  Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Y. Takeuchi,et al.  Restriction of lentivirus in monkeys , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Y. Takeuchi,et al.  Abrogation of Ref1 Retrovirus Restriction in Human Cells , 2002, Journal of Virology.

[91]  M. Dittmar,et al.  Characterization of a Late Entry Event in the Replication Cycle of Human Immunodeficiency Virus Type 2 , 2001, Journal of Virology.

[92]  Frederic D. Bushman,et al.  A quantitative assay for HIV DNA integration in vivo , 2001, Nature Medicine.

[93]  R. Tsien,et al.  Inhibition of NF-κB Activation by Arsenite through Reaction with a Critical Cysteine in the Activation Loop of IκB Kinase* , 2000, The Journal of Biological Chemistry.

[94]  G. Towers,et al.  Use of a Transient Assay for Studying the Genetic Determinants of Fv1 Restriction , 2000, Journal of Virology.

[95]  R. Tsien,et al.  Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. , 2000, The Journal of biological chemistry.

[96]  J. Sodroski,et al.  Species-Specific, Postentry Barriers to Primate Immunodeficiency Virus Infection , 1999, Journal of Virology.

[97]  A. Kingsman,et al.  Stable gene transfer to the nervous system using a non-primate lentiviral vector , 1999, Gene Therapy.

[98]  J. Young,et al.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[99]  F. Gao,et al.  Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes , 1999, Nature.

[100]  M. Malim,et al.  Evidence for a newly discovered cellular anti-HIV-1 phenotype , 1998, Nature Medicine.

[101]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[102]  D. Montefiori,et al.  A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3 , 1997, Journal of virology.

[103]  J. Sodroski,et al.  CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia , 1997, Nature.

[104]  J. Luban,et al.  Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses , 1996, Journal of virology.

[105]  F. Cosset,et al.  Retroviral retargeting by envelopes expressing an N-terminal binding domain , 1995, Journal of virology.

[106]  J. Young,et al.  Identification and characterization of the viral interaction determinant of the subgroup A avian leukosis virus receptor , 1995, Journal of virology.

[107]  H Hui,et al.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology , 1994, Journal of virology.

[108]  H. Varmus,et al.  A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor , 1993, Cell.

[109]  Jeremy Luban,et al.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B , 1993, Cell.

[110]  H. Varmus,et al.  Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro , 1992, Journal of virology.

[111]  C. Innes,et al.  Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line , 1990, Journal of virology.

[112]  Philip R. Johnson,et al.  An African primate lentivirus (SIVsmclosely related to HIV-2 , 1989, Nature.

[113]  M. Emerman,et al.  Genome organization and transactivation of the human immunodeficiency virus type 2 , 1987, Nature.

[114]  L. Montagnier,et al.  Molecular cloning and polymorphism of the human immune deficiency virus type 2 , 1986, Nature.

[115]  R. Desrosiers,et al.  Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. , 1985, Science.